Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial)
Open Access
- 10 October 2025
- journal article
- Published by Elsevier in Immuno-Oncology and Technology
- Vol. 29, 101077
Abstract
No abstract availableKeywords
Funding Information
- Roche
This publication has 37 references indexed in Scilit:
- SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophilsLung Cancer, 2022
- Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)Annals of Oncology, 2018
- The Immune Revolution: A Case for Priming, Not CheckpointCancer Cell, 2018
- Intratumoral immunotherapy: using the tumor as the remedyAnnals of Oncology, 2017
- Kick-starting the cancer-immunity cycle by targeting CD40OncoImmunology, 2015
- Tumor Immunotherapy Directed at PD-1New England Journal of Medicine, 2012
- Fc gamma receptors and cancerSpringer Seminars in Immunopathology, 2006
- CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacyNature Medicine, 1999
- Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40Nature Medicine, 1999
- CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell helpNature Medicine, 1999